<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33793036</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>2192</StartPage><EndPage>2199</EndPage><MedlinePgn>2192-2199</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.14849</ELocationID><Abstract><AbstractText Label="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is associated with a range of clinical phenotypes and shows progressive degeneration of upper and/or lower motor neurons, and phosphorylated 43&#xa0;kDa TAR DNA-binding protein (pTDP-43) inclusions in motor and non-motor pathways. Parkinsonian features have been reported in up to 30% of ALS patients, and Lewy bodies, normally associated with Lewy body disease (LBD), have been reported in a small number of ALS cases, with unknown clinical relevance. This study investigates the prevalence of clinically relevant LBD in a prospectively studied ALS cohort to determine whether concomitant pathology contributes to the clinical heterogeneity.</AbstractText><AbstractText Label="METHODS">All ALS cases held by the New South Wales Brain Bank (n&#xa0;=&#xa0;97) were screened for coexisting LBD consistent with clinical disease (Braak&#xa0;&#x2265;&#xa0;stage IV). Relevant clinical and genetic associations were determined.</AbstractText><AbstractText Label="RESULTS">Six cases had coexisting LBD Braak&#xa0;&#x2265;&#xa0;stage IV pathology. The age at symptom onset (69&#xa0;&#xb1;&#xa0;7&#xa0;years) and disease duration (4&#xa0;&#xb1;&#xa0;3&#xa0;years) in ALS cases with coexisting LBD did not differ from ALS cases. Three patients had lower limb onset and two patients had bulbar onset. Two patients developed the clinical features of Parkinson's disease, with one receiving a dual diagnosis. All cases had no known relevant family history or genetic abnormalities.</AbstractText><AbstractText Label="CONCLUSION">The prevalence of clinically relevant LBD pathology in ALS is higher than in the general population, and has implications for clinical and neuropathological diagnoses and the identification of biomarkers.</AbstractText><CopyrightInformation>&#xa9; 2021 European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Shelley L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0001-7863-5389</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Health and Human Sciences, School of Biomedical Sciences, Dementia Research Centre, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Discipline of Pathology and Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jordan Hanxi</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Discipline of Pathology and Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Sousa</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Discipline of Pathology and Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheong</LastName><ForeName>Rosie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Discipline of Pathology and Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crockford</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Discipline of Pathology and Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheedy</LastName><ForeName>Donna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Discipline of Pathology and Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Discipline of Pathology and Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCrossin</LastName><ForeName>Toni</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Discipline of Pathology and Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Rachel H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCann</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Randwick, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shepherd</LastName><ForeName>Claire E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Randwick, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Dominic B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Science, Faculty of Medicine, Health and Human Sciences, Centre for MND Research, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0003-0422-8398</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Australia, Randwick, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kril</LastName><ForeName>Jillian J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-9407-8674</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Health and Human Sciences, School of Biomedical Sciences, Dementia Research Centre, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, Discipline of Pathology and Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R28AA012725</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="Y">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lewy body</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">synuclein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>1</Day><Hour>12</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33793036</ArticleId><ArticleId IdType="doi">10.1111/ene.14849</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084-2098.</Citation></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131:1975-1978.</Citation></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942-955.</Citation></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Irwin DJ, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol. 2014;127:423-439.</Citation></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, et al. Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathol. 2016;131:571-585.</Citation></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503-1527.</Citation></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20-38.</Citation></Reference><Reference><Citation>Delisle MB, Gorce P, Hirsch E, Hauw JJ, Rascol A, Bouissou H. Motor neuron disease, parkinsonism and dementia. Report of a case with diffuse Lewy body-like intracytoplasmic inclusions. Acta Neuropathol. 1987;75:104-108.</Citation></Reference><Reference><Citation>Konagaya M, Kato T, Sakai M, et al. A clinical and pathological study of a Japanese case of Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex with family history. J Neurol. 2003;250:164-170.</Citation></Reference><Reference><Citation>Qureshi AI, Wilmot G, Dihenia B, Schneider JA, Krendel DA. Motor neuron disease with parkinsonism. Arch Neurol. 1996;53:987-991.</Citation></Reference><Reference><Citation>Klos KJ, Josephs KA, Parisi JE, Dickson DW. Alpha-synuclein immunohistochemistry in two cases of co-occurring idiopathic Parkinson's disease and motor neuron disease. Mov Disord. 2005;20:1515-1520.</Citation></Reference><Reference><Citation>Yamada T, Itoh K, Matsuo K, et al. Concomitant alpha-synuclein pathology in an autopsy case of amyotrophic lateral sclerosis presenting with orthostatic hypotension and cardiac arrests. Neuropathology. 2014;34:164-169.</Citation></Reference><Reference><Citation>Hainfellner JA, Pilz P, Lassmann H, Ladurner G, Budka H. Diffuse Lewy body disease as substrate of primary lateral sclerosis. J Neurol. 1995;242:59-63.</Citation></Reference><Reference><Citation>Kato T, Katagiri T, Hirano A, Sasaki H, Arai S. Sporadic lower motor neuron disease with Lewy body-like inclusions: a new subgroup? Acta Neuropathol. 1988;76:208-211.</Citation></Reference><Reference><Citation>Williams TL, Shaw PJ, Lowe J, Bates D, Ince PG. Parkinsonism in motor neuron disease: case report and literature review. Acta Neuropathol. 1995;89:275-283.</Citation></Reference><Reference><Citation>Hedera P, Lerner AJ, Castellani R, Friedland RP. Concurrence of Alzheimer's disease, Parkinson's disease, diffuse Lewy body disease, and amyotrophic lateral sclerosis. J Neurol Sci. 1995;128:219-224.</Citation></Reference><Reference><Citation>Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141:2181-2193.</Citation></Reference><Reference><Citation>Calvo A, Chi&#xf2; A, Pagani M, et al. Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study. J Neurol. 2019;266:1633-1642.</Citation></Reference><Reference><Citation>Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014;29:1583-1590.</Citation></Reference><Reference><Citation>Forrest SL, Crockford DR, Sizemova A, et al. Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration. Neurology. 2019;92:e2472-e2482.</Citation></Reference><Reference><Citation>Chare L, Hodges JR, Leyton CE, et al. New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. J Neurol Neurosurg Psychiatry. 2014;85:865-870.</Citation></Reference><Reference><Citation>Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837-844.</Citation></Reference><Reference><Citation>Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 2011;122:187-204.</Citation></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1-11.</Citation></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323-330.</Citation></Reference><Reference><Citation>Mackenzie IR, Arzberger T, Kremmer E, et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 2013;126:859-879.</Citation></Reference><Reference><Citation>Dobson-Stone C, Hallupp M, Bartley L, et al. C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology. 2012;79:995-1001.</Citation></Reference><Reference><Citation>Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.</Citation></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-1800.</Citation></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.</Citation></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.</Citation></Reference><Reference><Citation>Boeve BF. Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol. 2013;12:469-482.</Citation></Reference><Reference><Citation>Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2012;83:102-108.</Citation></Reference><Reference><Citation>McCluskey L, Vandriel S, Elman L, et al. ALS-Plus syndrome: non-pyramidal features in a large ALS cohort. J Neurol Sci. 2014;345:118-124.</Citation></Reference><Reference><Citation>Brait K, Fahn S, Schwarz GA. Sporadic and familial parkinsonism and motor neuron disease. Neurology. 1973;23:990-1002.</Citation></Reference><Reference><Citation>Wood EM, Falcone D, Suh E, et al. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol. 2013;70:1411-1417.</Citation></Reference><Reference><Citation>McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J. TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing. Brain Pathol. 2017;27:472-479.</Citation></Reference><Reference><Citation>Besser LM, Teylan MA, Nelson PT. Limbic Predominant Age-Related TDP-43 Encephalopathy (LATE): Clinical and Neuropathological Associations. J Neuropathol Exp Neurol. 2020;79:305-313.</Citation></Reference><Reference><Citation>Hasegawa I, Takeda A, Hatsuta H, et al. An autopsy case of globular glial tauopathy presenting with clinical features of motor neuron disease with dementia and iron deposition in the motor cortex. Neuropathology. 2018;38:372-379.</Citation></Reference><Reference><Citation>Tanaka H, Kawakatsu S, Toyoshima Y, et al. Globular glial tauopathy Type II: Clinicopathological study of two autopsy cases. Neuropathology. 2019;39:111-119.</Citation></Reference><Reference><Citation>Ahmed Z, Doherty KM, Silveira-Moriyama L, et al. Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol. 2011;122:415-428.</Citation></Reference><Reference><Citation>Zarranz JJ, Ferrer I, Lezcano E, et al. A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease. Neurology. 2005;64:1578-1585.</Citation></Reference><Reference><Citation>Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol. 2017;134:187-205.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>